14 October 2025 : Original article
Long-Term Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma After Liver Transplantation in Patients with or without Concurrent Hepatocellular Carcinoma
I-Ji Jeong
CEF 1, Shin Hwang ACDEF 1*, Chul-Soo Ahn BCF 1, Deok-Bog Moon BCF 1, Tae-Yong Ha BC 1, Gi-Won Song BCD 1, Dong-Hwan Jung BCD 1, Gil-Chun Park BC 1, Woo-Hyoung Kang BC 1, Young-In Yoon BC 1, Sung-Gyu Lee ABC 1
DOI: 10.12659/AOT.951088
Ann Transplant 2025; 30:e951088
Table 1 The clinicopathological profiles of patients with combined hepatocellular carcinoma-cholangiocarcinoma who underwent liver transplantation.
| Parameter | Value |
|---|---|
| Age (years) | 55.3±7.0 |
| Sex (n) Male: Female | 51: 9 |
| Background liver disease (n) | |
| HBV | 53 (88.3%) |
| ALD | 6 (10%) |
| Others | 1 (1.7%) |
| Serum AFP (n=60) | |
| Mean (ng/mL) | 250.9±1258.5 |
| Median (ng/mL) | 16.1 (1.1–9734) |
| Serum PIVKA-II (n=53) | |
| Mean (mAU/mL) | 109.1±238.9 |
| Median (mAU/mL) | 29 (5–1136) |
| Serum CA 19-9 (n=32) | |
| Mean (U/mL) | 23.6±21.1 |
| Median (U/mL) | 16.7 (3–119) |
| MELD score | 12.3±5.8 |
| Graft type (n) | |
| Living-donor right liver | 55 (%) |
| Living-donor dual graft | 2 (3.3%) |
| Whole-liver | 2 (3.3%) |
| ABO-incompatible LT (n) | 12 (20.0%) |
| Graft-to-recipient weight ratio | 1.02±0.34 |
| CHC tumor size (cm) | 2.5±1.7 |
| CHC tumor number (n) | |
| 1 | 51 (85.0%) |
| 2 | 5 (8.3%) |
| 3 or more | 4 (6.7%%) |
| CHC lymphovascular invasion (n) | 14 (23.3%) |
| CHC perineural invasion (n) | 1 (1.7%) |
| CHC lymph node metastasis (n) | 0 (0%) |
| CHC 8 edition AJCC tumor stage (n) | |
| IA | 27 (45.0%) |
| IB | 19 (31.7%) |
| II | 13 (21.7%) |
| IIIA | 1 (8.0%) |
| Very early-stage CHC (stage IA) without HCC (n) | 17 (28.3%) |
| Concurrent viable HCC (n) | 23 (38.3%) |
| Concurrent HCC 8 edition AJCC stage (n)* | |
| IA | 7 (30.4%) |
| IB | 2 (8.7%) |
| II | 13 (56.5%) |
| IIIA | 1 (4.3%) |
| * Denominator was 23. HBV – hepatitis B virus; ALD alcoholic liver disease; AFP – alpha-fetoprotein; PIVKA-II – proteins induced by vitamin K absence or antagonist-II; CA19-9 – carbohydrate antigen 19-9; MELD – model for end-stage liver disease; LT – liver transplantation; AJCC – American Joint Committee on Cancer tumor staging system; CHC – combined hepatocellular carcinoma-cholangiocarcinoma; HCC – hepatocellular carcinoma. | |